Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BOTOX for the Treatment of Urinary Incontinence due to Neurogenic Detrusor Overactivity in Patients with Multiple Sclerosis.

Next Previous
Trial Profile

BOTOX for the Treatment of Urinary Incontinence due to Neurogenic Detrusor Overactivity in Patients with Multiple Sclerosis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Neurogenic bladder; Urinary incontinence
  • Focus Registrational; Therapeutic Use
  • Sponsors Allergan

Most Recent Events

  • 20 Jul 2018 Results published in the Neurology
  • 10 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov .
  • 11 Mar 2014 Planned end date changed from 1 Jun 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top